Lyra Therapeutics clears path to Phase III for new ENT treatment option

9 June 2021

USA-based drug developer Lyra Therapeutics (Nasdaq: LYRA) saw its shares gain more than 14% to $9.00 in pre-market trading today, as it announced the positive outcome of the company’s end-of-Phase II meeting with the Food and Drug Administration, establishing the key elements of the upcoming Phase III study for LYR-210, the company’s lead product candidate for the treatment of chronic rhinosinusitis.

This and other recent news show Lyra’s momentum in the ENT (ear, nose and throat) therapeutics area, and clears the regulatory path to Phase III. Last week Lyra announced a $135 million international strategic partnership and license agreement with Sino-American biotech firm LianBio for developing LYR-210 in Asia.

Based on the Agency’s suggestion, Lyra intends to enroll a total of around 350 subjects split into two replicate, largely concurrent Phase III clinical trials, each powered to >95% to detect statistical significance. Both studies will evaluate a 7500µg dose of LYR-210, and additional key clinical aspects of the studies will also be the same.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK